SCHEMBL637302

SCHEMBL637302

O=c1cc(C=Cc2ccc(Cl)cc2)nc2sccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
RXFP1 Q9HBX9 2/20 0.44
MAPT P10636 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 1/20 0.41
POLB P06746 3/20 0.40
CYP1A2 P05177 1/20 0.40
KDR P35968 1/20 0.39
AHR P35869 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL637301 1.00 LMNA (0.47) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10990759 0.87 L3MBTL1 (0.46) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10997234 0.87 POLB (0.47) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10997612 0.86 HPGD (0.44) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10994731 0.85 POLB (0.43) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10993150 0.84 MAPT (0.45) LMNAL3MBTL1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10995570 0.81 MAPT (0.45) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10999311 0.79 NPC1 (0.40) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL11000849 0.79 TP53 (0.50) LMNAPKML3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL10993254 0.79 NPC1 (0.47) LMNAL3MBTL1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283017-B1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2015-08-05 EP disclosed
US-8518955-B2 Fused pyrimidineone compounds as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
EP-2626360-A1 Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators Glenmark Pharmaceuticals S.A. (CH) 2013-08-14 EP disclosed
US-20120115886-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. 2012-05-10 US disclosed
US-20120108813-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. 2012-05-03 US disclosed
US-8119647-B2 Fused pyrimidineone compounds as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2012-02-21 US disclosed
US-20090286811-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286811-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV4 LMNA 2744/4885PKM 894/4885L3MBTL1 4747/4885
US-20120115886-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV4 LMNA 2744/4885PKM 894/4885L3MBTL1 4747/4885
US-20120108813-A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV4 LMNA 2744/4885PKM 894/4885L3MBTL1 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.